Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oculis Holding (OCS)
NASDAQ:OCS
Oculis Holding (OCS) Stock Price & Analysis
29 Followers
OCS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.05 - $14.50
Previous Close$11.55
Volume36.00
Average Volume (3M)29.42K
Market Cap
$481.64M
Enterprise Value$379.20M
Total Cash (Recent Filing)$91.65M
Total Debt (Recent Filing)$605.00K
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Aug 14, 2024EPS Estimate
-$0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding36,649,705
10 Day Avg. Volume8,503
30 Day Avg. Volume29,419
Standard Deviation0.16
R-Squared0.00614
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)5.26
Price to Sales (P/S)485.62
Price to Cash Flow (P/CF)-8.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit429.45
Enterprise Value/Ebitda-1.02K
Forecast
1Y Price Target
$27.25Price Target Upside133.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Oculis Holding News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe combined results could allow the company to advance licaminlimab into a Phase 3 program.
Market StrategyThe strategy could confer premium pricing and favorable access relative to marketed brands.
Product PotentialEarly data for both assets have been compelling, and there is a meaningful market opportunity for OCS-01 as the first topical for diabetic macular edema.
Bears Say
EfficacyThe durability of Restoret's efficacy is not clear.
Market UseRestoret may be primarily used in patients who have already exhibited suboptimal response to anti-VEGFs if and when it reaches the market.
Program SuccessThe small size of the patient sub-group limits the ability to increase program odds-of-success.
---
Ownership Overview
0.00%
Insiders
0.03% Mutual Funds
0.25% Other Institutional Investors
99.72% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
OCS FAQ
What was Oculis Holding’s price range in the past 12 months?
Oculis Holding lowest stock price was $9.05 and its highest was $14.50 in the past 12 months.
What is Oculis Holding’s market cap?
Currently, no data Available
When is Oculis Holding’s upcoming earnings report date?
Oculis Holding’s upcoming earnings report date is Aug 14, 2024 which is in 23 days.
How were Oculis Holding’s earnings last quarter?
Oculis Holding released its earnings results on May 08, 2024. The company reported -$0.495 earnings per share for the quarter, missing the consensus estimate of -$0.412 by -$0.083.
Is Oculis Holding overvalued?
According to Wall Street analysts Oculis Holding’s price is currently Undervalued.
Does Oculis Holding pay dividends?
Oculis Holding does not currently pay dividends.
What is Oculis Holding’s EPS estimate?
Oculis Holding’s EPS estimate is -$0.46.
How many shares outstanding does Oculis Holding have?
Oculis Holding has 41,700,000 shares outstanding.
What happened to Oculis Holding’s price movement after its last earnings report?
Oculis Holding reported an EPS of -$0.495 in its last earnings report, missing expectations of -$0.412. Following the earnings report the stock price went down -3.314%.
Which hedge fund is a major shareholder of Oculis Holding?
Among the largest hedge funds holding Oculis Holding’s share is Saba Capital Management. It holds Oculis Holding’s shares valued at N/A.
---
Oculis Holding Stock Smart Score
Company Description
Oculis Holding
European Biotech Acquisition Corp is a blank check company.
---
OCS Stock 12 Month Forecast
Average Price Target
$27.25
▲(133.30% Upside)
Technical Analysis
Best Analysts Covering OCS
1 Year
1 Year Success Rate
3/6 ratings generated profit
1 Year Average Return
+0.88%
assigned a buy rating 5 months ago
Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +0.88% per trade.
---